

NZX/ASX Announcement

4 March 2024

TruScreen Raises Initial NZ\$500,000 in Share Placement

Truscreen Group Limited (NZX/ASX:TRU) is pleased to advise that further to the announcement of 12 February 2024 “Truscreen to lodge a pro rata renounceable rights issue”, the Company has received firm commitments from a number of investors for an initial Placement of 25,000,000 shares at NZ\$0.02 each to raise NZ\$500,000, before costs.

The shares will be issued under its existing 15% placement capacity. This Placement is in addition to the Oversubscription Bookbuild which will take place on 14th and 15th March 2024.

Tony Ho Chairman commented, “*we are pleased with the strong support we have received at the start of this capital raise, and encourage shareholders to ensure their applications are completed before the closing date on 13 March 2024*”.

In the event shareholders have not received application forms please contact the share registry Link Market Services:

enquiries@linkmarketservices.co.nz T +64 9 375 5998 or the Company Secretary, contact details below.

This announcement has been approved by the Board.

Ends

Guy Robertson
Company Secretary
Tel: +61 407 983 270
Email: guyrobertson@truscreen.com

For more information, visit www.truscreen.com or contact:

Mr Martin Dillon
Chief Executive Officer
martindillon@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra[®], is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In financial year 2023 alone, over 140000* examinations have been performed with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer"[®].

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*